‘Contribution of component’ and the perioperative immune-checkpoint inhibitor precedent von Strohbehn, Garth W., Gyawali, Bishal

Volltext

Targeted randomization dose optimization trials enable fractional dosing of scarce drugs von Boonstra, Philip S, Tabarrok, Alex, Strohbehn, Garth W

Volltext

New strategies for dose optimization in oncology: insights from targeted small-molecule therapies for metastatic or advanced non-small cell lung cancer von Strohbehn, Garth W

Volltext

Association Between Administration of IL-6 Antagonists and Mortality Among Patients Hospitalized for COVID-19: A Meta-analysis von Shankar-Hari, Manu, Vale, Claire L, Godolphin, Peter J, Fisher, David, Higgins, Julian P. T, Spiga, Francesca, Savovic, Jelena, Tierney, Jayne, Baron, Gabriel, Benbenishty, Julie S, Berry, Lindsay R, Broman, Niklas, Cavalcanti, Alexandre Biasi, Colman, Roos, De Buyser, Stefanie L, Derde, Lennie P. G, Domingo, Pere, Omar, Sharifah Faridah, Fernandez-Cruz, Ana, Feuth, Thijs, Garcia, Felipe, Garcia-Vicuna, Rosario, Gonzalez-Alvaro, Isidoro, Gordon, Anthony C, Haynes, Richard, Hermine, Olivier, Horby, Peter W, Horick, Nora K, Kumar, Kuldeep, Lambrecht, Bart N, Landray, Martin J, Leal, Lorna, Lederer, David J, Lorenzi, Elizabeth, Mariette, Xavier, Merchante, Nicolas, Misnan, Nor Arisah, Mohan, Shalini V, Nivens, Michael C, Oksi, Jarmo, Perez-Molina, Jose A, Pizov, Reuven, Porcher, Raphael, Postma, Simone, Rajasuriar, Reena, Ramanan, Athimalaipet V, Ravaud, Philippe, Reid, Pankti D, Rutgers, Abraham, Sancho-Lopez, Aranzazu, Seto, Todd B, Sivapalasingam, Sumathi, Soin, Arvinder Singh, Staplin, Natalie, Stone, John H, Strohbehn, Garth W, Sunden-Cullberg, Jonas, Torre-Cisneros, Julian, Tsai, Larry W, van Hoogstraten, Hubert, van Meerten, Tom, Veiga, Viviane Cordeiro, Westerweel, Peter E, Murthy, Srinivas, Diaz, Janet V, Marshall, John C, Sterne, Jonathan A. C

Volltext

Special designations and the US Food and Drug Administration's "dual mandate" von Strohbehn, Garth W, Ratain, Mark J

Volltext

Combining atezolizumab 1200 mg with bevacizumab 15 mg/kg: based on science or just revenues? von Ratain, Mark J., Strohbehn, Garth W.

Volltext

Sotorasib dosing and incremental cost ineffectiveness — implications and lessons for stakeholders von Strohbehn, Garth W., Ratain, Mark J.

Volltext

Prognostic and predictive value of neutrophil-to-lymphocyte ratio with adjuvant immunotherapy in stage III non-small-cell lung cancer von Bryant, Alex K., Sankar, Kamya, Strohbehn, Garth W., Zhao, Lili, Elliott, David, Qin, Angel, Yentz, Sarah, Ramnath, Nithya, Green, Michael D.

Volltext

Lorlatinib Exposed: A Far From Optimal Dose von Strohbehn, Garth W., Ratain, Mark J.

Volltext

Clinical Uncertainty von Kacew, Alec J, Strohbehn, Garth W

Volltext

Interventional Pharmacoeconomics: A Novel Mechanism for Unlocking Value von Serritella, Anthony V., Strohbehn, Garth W., Goldstein, Daniel A., Lichter, Allen S., Ratain, Mark J.

Volltext

Registration trials in countries without access to US standards of care — pitfalls of interpretation von Strohbehn, Garth W., Goldstein, Daniel A.

Volltext

De-escalating adjuvant durvalumab treatment duration in stage III non-small cell lung cancer von Bryant, Alex K., Sankar, Kamya, Zhao, Lili, Strohbehn, Garth W., Elliott, David, Moghanaki, Drew, Kelley, Michael J., Ramnath, Nithya, Green, Michael D.

Volltext

Applied Clinical Pharmacology in a Crisis: Interleukin‐6 Axis Blockade and COVID‐19 von Strohbehn, Garth W., Reid, Pankti D., Ratain, Mark J.

Volltext

Mistaking the Trees for the Forest? von Strohbehn, Garth W., Daugherty, Christopher K.

Volltext

Palbociclib: a new partner for cetuximab? von Strohbehn, Garth W, Vokes, Everett E

Volltext

Artificial Intelligence Can Cut Costs While Maintaining Accuracy in Colorectal Cancer Genotyping von Kacew, Alec J, Strohbehn, Garth W, Saulsberry, Loren, Laiteerapong, Neda, Cipriani, Nicole A, Kather, Jakob N, Pearson, Alexander T

Volltext

Highly penetrative, drug-loaded nanocarriers improve treatment of glioblastoma von Zhou, Jiangbing, Patel, Toral R., Sirianni, Rachael W., Strohbehn, Garth, Zheng, Ming-Qiang, Duong, Nha, Schafbauer, Thomas, Huttner, Anita J., Huang, Yiyun, Carson, Richard E., Zhang, Ying, Sullivan, David J., Piepmeier, Joseph M., Saltzman, W. Mark

Volltext

Immunotherapy and the A2A Adenosine Receptor: A Confounding Brew von Strohbehn, Garth W., Ratain, Mark J.

Volltext

Combination therapy patents: a new front in evergreening von Strohbehn, Garth W, Kacew, Alec J, Goldstein, Daniel A, Feldman, Robin C, Ratain, Mark J

Volltext